Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies.
The business
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
Small Caps Research
No research on Paradigm Biopharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PAR based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Paradigm’s iPPS shown to reduce cartilage loss and improve function in osteoarthritis patients
Late-stage drug development company Paradigm Biopharmaceuticals (ASX: PAR) has announced positive study data from a Phase 2 clinical trial of injectable pentosan polysulfate sodium (iPPS) for the treatment of acute pain associated with knee osteoarthritis. The study investigated changes in synovial fluid biomarkers with iPPS treatment compared with placebo in 61 participants administered with twice-weekly […]
Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise
Paradigm Biopharmaceuticals (ASX: PAR) has announced trial patients being treated with its injectable pentosan polysulfate sodium (iPPS) drug for osteoarthritis of the knee have confirmed improved knee function and pain reduction for six months. The biotechnology company today confirmed its phase 2b clinical trial has successfully met its key secondary endpoints of improved knee function […]
Paradigm Biopharmaceuticals advances Zilosul osteoarthritis program, to trial drug in MPS patients
Paradigm Biopharmaceuticals (ASX: PAR) has completed treatment of its Zilosul injectable pentosan polysulfate (iPPS) drug under the US Food and Drug Administration’s expanded access program, while collaring FDA orphan status for using it in treating MPS-I. Also known as compassionate use, the expanded access program provides a pathway for doctors to use investigational drugs, biologics […]
Paradigm doses all trial patients with Zilosul while dodging COVID-19 impact
An experimental treatment for knee osteoarthritis developed by Paradigm Biopharmaceuticals (ASX: PAR), Zilosul, has now been dosed in all ten patients under the FDA approved expanded access – otherwise known as compassionate use – program in the US. In a statement to investors, Paradigm said patients being treated are at different stages of the treatment […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.